Η GKardia στο 1ο συνέδριο της Κυπριακής εταιρείας Καρδιάς
H GKardia συνεχίζει να βρίσκεται στις επάλξεις της Καρδιοαγγειοχειρουργικής και των νεώτερων εξελίξεων της. Και δεν θα μπoρούσε να υπάρχει καλύτερη αφορμή από το πρώτο συνέδριο της Κυπριακής εταιρείας Καρδιάς, Θώρακος και Μεγάλων Αγγείων το Σάββατο 6 Απριλίου 2024, για να παρουσιαστεί το COR-KNOT στην ιατρική Καρδιοχειρουργική κοινότητα της Κύπρου που το έχει αγκαλιάσει και το χρησιμοποιεί στην καθημερινή χειρουργική ρουτίνα της.
TAVR market 1HALF2022-Greece
news TAVR market 1HALF2022-Greece Gregory Krinos Global TAVR procedures are evolving with more than $5B market size at present and continuous evolution expected in upcoming years estimated to reach $10B by 2028 mainly driven by indication expansion (low risk approval), therapy awareness and technology advances. Despite this evolution, diagnosis and treatment rates of Aortic Stenosis […]
CENTRAL PROCUREMENT AUTHORITY ANNOUNCEMENT FOR CONSULTATION RELATED TO TAVR VALVES TENDER FOR 2 YEARS IN GREECE- DEC2022
news CENTRAL PROCUREMENT AUTHORITY ANNOUNCEMENT FOR CONSULTATION RELATED TO TAVR VALVES TENDER FOR 2 YEARS IN GREECE- DEC2022 Gregory Krinos t is widely known that the hashtag#TAVR market is very dynamic, and it grows around 20%+ in an annual basis in our country Greece. Self-Expandable (SE) vs Balloon Expandable (BE) ratio is 79%-21% respectively at […]
GREECE TAVR 2016-2025
news GREECE TAVR 2016-2025 Gregory Krinos Preliminary #1H2023 #TAVR procedural highlights in #Greece include : around 806 procedures directly aligned with our estimation one year ago for 1600+ implants by the end of 2023 translated to a growth of around 28% vs PY. Around 56% of the procedures are performed in public and hybrid hospitals […]
Transcatheter Aortic valve Replacement(TAVR) Market 2020-Greece
news Transcatheter Aortic valve Replacement(TAVR) Market 2020-Greece Gregory Krinos Global TAVR procedures are evolving with around $4B market size at present and continuous evolution expected in upcoming years estimated to reach $7B by 2024 mainly driven by indication expansion (low risk approval), therapy awareness and technology advances. Despite this evolution, diagnosis and treatment rates of […]